

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

SUPPLEMENTAL ANNOUNCEMENT REGARDING ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME

Reference is made to the announcement (the “**Announcement**”) of Keymed Biosciences Inc. (the “**Company**”) dated January 21, 2022. Unless otherwise specified, capitalized terms used herein shall have the meaning as those defined in the Announcement.

The Board would like to supplement that with reference to the paragraph headed “VIII. Restrictions” of the Announcement, a Grant under the Scheme must not be made after inside information has come to the Company’s knowledge and this shall include the period of:

- (a) sixty (60) days immediately preceding the publication date of the annual results or, if shorter, the period from the end of the relevant financial year up to the publication date of the results; and
- (b) thirty (30) days immediately preceding the publication date of the quarterly results (if any) and half-year results or, if shorter, the period from the end of the relevant quarterly or half-year period up to the publication date of the results.

In the course of administering the Scheme, the Company and the Committee will also comply with the applicable provisions of the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) set forth in Appendix 10 of the Listing Rules and applicable rules on insider dealing. No instructions will therefore be given to the Trustee to acquire Shares under the Scheme at a time when any Director is in possession of unpublished inside information or where dealings by Directors are prohibited under any code or requirement of the Listing Rules and all applicable laws from time to time (“**Relevant Time**”). As the Trustee will be acquiring the Shares on the instruction of the Committee, the Trustee will also not acquire any Shares during the Relevant Time.

The Company and the Committee will continue to administer the scheme such that the (i) Grant of Awards under the Scheme, (ii) purchase of Shares by the Trustee; and (iii) the Committee giving instruction to the Trustee to purchase Shares for the administration of the Scheme will be conducted in accordance with the applicable provisions of the Model Code.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, January 28, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Dong LYU, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.